• WhatNextEmails' Avatar

    WhatNextEmails asked a questionColorectal (Colon) Cancer

    We have an email asking about Opioid induced constipation, can you share any experiences if you have had any with this?

    12 answers
    • alivenwell's Avatar

      Although I take no opioids, I have experienced extreme constipation. I try to make a habit out of staying hydrated and eating yogurt.

      25 days ago
    • MerryMaid's Avatar

      I am still in treatment and the pain in my throat and mouth is unbearable. I am taking quite a bit of pain meds and yeah, I got that.

      24 days ago
    • EmpathAgain's Avatar

      Unfortunately, the problem with opiod-induced constipation is it will usually last as long as you're taking opiods. Your body will likely develop a tolerance to quite a few of the opiod-induced side effects you may experience from your pain pills, but constipation is not likely to be one of the issues that loosenswith time or exposure.

      It astounds me how much of a problem constipation from chronic use of pain pills (even completely adhering to your prescription, eating a healthy diet, drinking plenty of water), can really be. For a while I was at a point where each time I had a bowel movement felt like a cause for celebration. Simultaneously hurt so bad, yet also felt so relieving being able to get it out. The slowness and fullness you feel from pain pills made me feel older and more tired until I lowered the amount I took, despite it being far less than mybdoxtors were trying to put me on, but it wasn't worth the costs to get the benefits, so while still taking some pain medication and being grateful I have it near if needed, I avoid using it when I know I can get by without having to take any.

      Another problem with opiod-induced constipation is that adding fiber to your diet doesn't actually help with this specific type of constipation. In fact it can make it worse, because you're adding a lot of bulk, but without any movement, so it's like you have a lump of fiber that need a to pass on top of what you're body was trying to expel out to begin with, heh. Stool softeners provide a little bit of relief and allow you to have a BM likely a day or two before before you would go without them, it's hard to get used to this particular pain medication side effect. I recognize how hard it can be to get by without anything to help with pain though, so making sure to just stay hydrated, walk/exercise, and making sure not to strain yourself while on the toilet are all key, but not perfect fixes. I haven't ever tried the medications now out for opiod-induced constipation, but that could potentially be an answer (Also, would require having to take an extra pill, when I know too many of us on here have more than enough pills to take every day, not sure if you want to add more, gourself). Coffee/caffeine can help relieve constipation to some degree, just to get you moving a bit down stairs, heh. A couple glasses of wine helps me move a little as well, but There s not one surefire, effective, and consistent reprieve from opiod-induced constipation as long as you are on opiods.

      12 days ago
  • WhatNextEmails' Avatar
  • WhatNextEmails' Avatar

    WhatNextEmails asked a questionCancer

    This question was emailed to us: Has anyone developed a nervous tick or habit since diagnosis?

    • GregP_WN's Avatar

      Not really a habit or tick, but I have to make a growling or gargling noise when I eat sometimes to get things to go down. It's exciting to be around me sometimes when I'm eating.

      3 months ago
    • LiveWithCancer's Avatar

      I haven't. I've had involuntary muscle movements for years before chemotherapy.

      3 months ago
    • SandiA's Avatar

      My face moves on the right side when I am nervous. Pre cancer the last time I noticed it was when I had an interview for a new position at my school. Never gave it much thought after that, but I have noticed it will happen often when I am having scans especially a MRI. The actual scan doesn’t make me nervous but I think it might be just the thought of what they may find. Not sure but it almost always happens when I go in the machine. I keep waiting for them to tell me to stay still but I honestly can’t help it.

      3 months ago
  • WhatNextEmails' Avatar
  • WhatNextEmails' Avatar

    WhatNextEmails shared a photo


    Targeting Cancer-The dawn of precision medicine
    INNEA OLSON tells her story—of repeatedly facing death, then being saved by the latest precision therapy—articulately and thoughtfully, agreeing to discuss subjects that might otherwise be too personal, she says, because it could benefit other patients. She lives in an artist cooperative in Lowell, Massachusetts, in an industrial space, together with her possessions and artwork, which fill most of an expansive high-ceilinged room. Olson is tall, with close-cropped, wavy blonde hair, and dresses casually in faded blue jeans. Although she has an open, informal style, this is paired with a natural dignity and a deliberate manner of speaking.

    “I had a young doctor who was very good,” she begins. “I presented with shortness of breath and a cough, and also some strange weakness in my upper body. And he ordered a chest x-ray.” Years later, she saw in her chart that he had written, “On the off chance that this young, non-smoking woman has a neoplasm”—the beginnings of a tumor in her left lung. But he didn’t mention that to her, and “he ended up getting killed on 9/11—he was on one of the planes that hit the towers.”

    The national tragedy thus rippled into Olson’s life. Never suspecting that her symptoms could be caused by cancer, she spent the next several years seeking a diagnosis. A string of local doctors told her it was adult-onset asthma, hypochondria, then pneumonia. When antibiotics didn’t clear the pneumonia, a CT scan showed a five-centimeter mass in her left lung: an infection? Or cancer? It was the first time she had heard that word. The technicians told her that at 45, she was too young for that. But a biopsy confirmed the diagnosis. “In 2005, when you told someone they had lung cancer,” a doctor later told her, “you were basically saying you were sorry.” Her youngest son was seven at the time. Olson wanted to live.

    Now, 13 years later, she is alive and healthy, a testament to the potential of precision medicine to extend lives. But like precision medicine itself, her story encapsulates the best and worst of what medicine can offer, as converging forces in genetics, data science, patient autonomy, health policy, and insurance reimbursement shape its future. There are miraculous therapies and potentially deadly side effects; tantalizing quests for cures that come at increasingly high costs; extraordinary advances in basic science, despite continuing challenges in linking genes implicated in disease to biological functions; inequities in patient care and clinical outcomes; and a growing involvement of patients in their own care, as they share experiences, emotions, and information with a global online community, and advocate for their own well-being.

    Precision medicine is not really new. Doctors have always wanted to deliver increasingly personalized care. The current term describes a goal of delivering the right treatment to the right patient at the right time, based on the patient’s medical history, genome sequence, and even on information, gathered from wearable devices, about lifestyle, behaviors, or environmental exposures: healthcare delivered in an empiric way. When deployed at scale, this would, for example, allow doctors to compare their patient’s symptoms to the histories of similar patients who have been successfully treated in the past. Treatments can thus be tailored to particular subpopulations of patients. To get a sense of the promise of precision medicine—tantalizingly miraculous at times, yet still far from effective implementation—the best example may be cancer, which kills more than 595,000 Americans each year.

    See complete Article Here - From Harvard Magazine

  • WhatNextEmails' Avatar

    WhatNextEmails posted an update

    Lymphoma News Today Sent This Out to be Shared

    Rich’s RP-323 Shows Activity Against Hodgkin’s Lymphoma in Phase 1 Trial

    Experimental therapy RP-323 has shown anticancer activity against Hodgkin’s lymphoma in a Phase 1 trial. Its developer, Rich Pharmaceuticals, is now planning to evaluate the therapy in human clinical trials for the disease.

    “We look forward to being able to commence clinical trials in the future to prove that using RP-323 alone or in combination with other anticancer agents will have significant therapeutic activity against Hodgkin’s lymphoma,” Ben Chang, CEO of Rich Pharmaceuticals, said in a press release.

    RP-323 is a natural molecule isolated and purified from croton oil, which is obtained from the seeds of the purging croton, a plant native to Southeast Asia.

    The investigative therapy not only modulates cancer cell behavior, including their survival and growth, but it also promotes immune cell proliferation. This suggests it could work as an immunotherapy to boost the immune system. Given its broad effect, RP-323 represents an attractive option to target cancer.

    A Phase 1 study (NCT00004058) evaluated the anticancer potential of ascending doses of RP-323 in patients with relapsed or refractory blood malignancies or bone marrow disorders.

    The trial, led by Roger Strair, MD and PhD, oncologist at The Cancer Institute of New Jersey, included 35 patients. Participants received RP-323 infusions for five days over two consecutive weeks, followed by a two-week resting period before another treatment cycle.

    Only one patient — with relapsed or refractory Hodgkin’s lymphoma with a chest wall lesion — responded to the treatment. After three weeks of treatment with a 0.063 mg/m2 dose, the tumor had reduced from 7 cm to 2.5 cm in size. However, the tumor mass increased in size later on and treatment was stopped.

    “A phase 1 clinical trial conducted at The Cancer Institute of New Jersey [has] shown that RP-323 treatment reduced a palpable tumor mass after three weeks in a patient with Hodgkin’s lymphoma,” Chang said.

    While the patient relapsed in the trial, researchers believe the therapy candidate may have potential for Hodgkin’s lymphoma, supporting Phase 2 clinical studies.

    Results from the trial were published in the journal Cancer Chemotherapy and Pharmacology, in the study “A Phase I clinical trial with 12-O-tetradecanoylphorbol-13-acetate for patients with relapsed refractory malignancies.”

    Rich Pharmaceuticals has also tested RP-323’s safety and efficacy in patients with relapsed or refractory acute myeloid leukemia and myelodysplatic syndrome — a group of blood disorders where immature blood cells never reach a fully mature state.